Breaks Categories: News

TuesdayFeb 07, 2023 11:59 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first patient in Spain. As part of the trial, the company has opened 37 of 59 planned clinical trial sites; the sites are located in the United States, Italy, France, Spain and Switzerland. The company noted that it plans an interim analysis of the study when…

Continue Reading

MondayFeb 06, 2023 2:00 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is the subject of an updated report released from Aegis Capital Corp. The update reflects the strong results from BVXV’s latest animal study indicating that anti-COVID-19 NanoAb can prevent infection. According to the report, BiondVax reported that in a continuation of the study, COVID-19 illness was virtually prevented in hamsters that received BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2. The report noted that data gathered from the preclinical trial show that BiondVax’s…

Continue Reading

FridayFeb 03, 2023 10:34 am

BioMedNewsBreaks – Cosmos Health Inc. (NASDAQ: COSM) Begins Process for Upstream Dual Listing

Cosmos Health (NASDAQ: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, has begun the application process to dual list its shares on Upstream. A trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. According to the announcement, Cosmos anticipates that the dual listing will provide the company with access to a global, digital-first investor base, enabling investors to trade with USDC digital currency as well as credit, debit, PayPal and USD; the move should increase the company’s liquidity, enhance price…

Continue Reading

ThursdayFeb 02, 2023 3:12 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the BIO CEO & Investor Conference. The event is slated to take place in New York from Feb. 6-9, 2023. Reichman’s presentation, scheduled to begin at 4:15 p.m. ET on Feb. 6, will focus on recent successful preclinical in vivo results of BiondVax’s innovative inhaled COVID-19 treatment. The presentation will also cover additional pipeline plans, including nanosized VHH-antibodies (“NanoAbs”) for the treatment of autoimmune diseases, such…

Continue Reading

ThursdayFeb 02, 2023 11:34 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent’s allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress disorder (“PTSD”). With the patent, the company expands its intellectual property and technology rights for the treatment of rare diseases. “After a comprehensive review by USPTO, we are pleased with the scope of the granted…

Continue Reading

WednesdayFeb 01, 2023 11:30 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Reappointment of Dr. Hector Alila to Establish Advisory Group

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced that Dr. Hector Alila has rejoined its board of directors with the specific responsibility of building a technical advisory board. “We are pleased to welcome Hector back to our board. With our focus on new scientific and clinical programs, our immediate need is to build a top-tier team of technical advisors to review our R&D activities and scientific approaches,” said Dr. Glynn Wilson, board chairman. “Dr. Alila brings 30 years of experience in translating novel research into clinical programs and product opportunities. He was most…

Continue Reading

WednesdayFeb 01, 2023 11:16 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial that evaluates deuterated DMT in humans, the study is being conducted at the Centre for Human Drug Research in the Netherlands; it is the largest-ever Phase 1 DMT trial conducted to date. Based on previous studies, CYB004 has shown potential to deliver an improved bioavailability…

Continue Reading

TuesdayJan 31, 2023 11:20 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has announced a stock repurchase program. According to the company, its board of directors has approved the program, which will acquire up to $1 million of the company's common stock. The announcement noted that the company could purchase common stock in a variety of ways, including in the open market and through privately negotiated transactions; all transactions will be in compliance with United States Securities and Exchange Commission rules and guidelines. The repurchase of stocks will depend on available liquidity, cash flows and market conditions…

Continue Reading

MondayJan 30, 2023 11:00 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 for the treatment of chronic pain associated with idiopathic MCAS (“MCAD”) at two clinical sites in the USA, with a Canadian site to be ready to recruit soon. “FSD201 is a unique proprietary formulation of palmitoyl ethanolamide, and already received the new molecular entity (‘NME’) designation for a potential 505(b)(1) application to the U.S. FDA. This…

Continue Reading

ThursdayJan 26, 2023 1:45 pm

BioMedNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Featured in New Article

MetAlert (OTC: MLRT), a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders, recently announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec LLC. Offering affordable, scalable location-awareness technology solutions, TrakTec made the news in a new Fairmont Post article that discusses its SafetyNet(R) service and others like it that are providing peace of mind for caregivers and loved ones and helping to quickly locate individuals who may be in danger. “Many police departments in the country have already begun to take advantage of these technologies to locate and rescue…

Continue Reading